Literature DB >> 25659759

Cancer stem cell: fundamental experimental pathological concepts and updates.

Farhadul Islam1, Bin Qiao2, Robert A Smith3, Vinod Gopalan1, Alfred K-Y Lam4.   

Abstract

Cancer stem cells (CSCs) are a subset of cancer cells which play a key role in predicting the biological aggressiveness of cancer due to its ability of self-renewal and multi-lineage differentiation (stemness). The CSC model is a dynamic one with a functional subpopulation of cancer cells rather than a stable cell population responsible for tumour regeneration. Hypotheses regarding the origins of CSCs include (1) malignant transformation of normal stem cells; (2) mature cancer cell de-differentiation with epithelial-mesenchymal transition and (3) induced pluripotent cancer cells. Surprisingly, the cancer stem cell hypothesis originated in the late nineteenth century and the existence of haematopoietic stem cells was demonstrated a century later, demonstrating that the concept was possible. In the last decade, CSCs have been identified and isolated in different cancers. The hallmark traits of CSCs include their heterogeneity, interaction with microenvironments and plasticity. Understanding these basic concepts of CSCs is important for translational applications using CSCs in the management of patients with cancer.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer stem cell; Heterogeneity; Microenvironment; Origin; Plasticity

Mesh:

Year:  2015        PMID: 25659759     DOI: 10.1016/j.yexmp.2015.02.002

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  36 in total

Review 1.  Upregulation of β3-adrenoceptors-a general marker of and protective mechanism against hypoxia?

Authors:  Massimo Dal Monte; Bronwyn A Evans; Ebru Arioglu-Inan; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-12-18       Impact factor: 3.000

2.  Temozolomide resistance and tumor recurrence: Halting the Hedgehog.

Authors:  Jessian L Munoz; Vivian Rodriguez-Cruz; Nykia D Walker; Steven J Greco; Pranela Rameshwar
Journal:  Cancer Cell Microenviron       Date:  2015-05-07

Review 3.  Cancer stem cells and chemoresistance: The smartest survives the raid.

Authors:  Jihe Zhao
Journal:  Pharmacol Ther       Date:  2016-02-17       Impact factor: 12.310

4.  Oct-4 and CD44 in epithelial stem cells like of benign odontogenic lesions.

Authors:  Eduardo Alonso Cruz Monroy; Pedro Paulo de Andrade Santos; Maria Luiza Diniz de Sousa Lopes; Adalberto Mosqueda-Taylor; Leão Pereira Pinto; Lélia Batista de Souza
Journal:  Histochem Cell Biol       Date:  2018-07-03       Impact factor: 4.304

5.  Silencing VDAC1 to Treat Mesothelioma Cancer: Tumor Reprograming and Altering Tumor Hallmarks.

Authors:  Swaroop Kumar Pandey; Renen Machlof-Cohen; Manikandan Santhanam; Anna Shteinfer-Kuzmine; Varda Shoshan-Barmatz
Journal:  Biomolecules       Date:  2022-06-27

6.  LncRNA NUTM2A-AS1 aggravates the progression of hepatocellular carcinoma by activating the miR-186-5p/KLF7-mediated Wnt/beta-catenin pathway.

Authors:  Jianwu Long; Longfei Liu; Xuefeng Yang; Xiaojun Zhou; Xianzhou Lu; Lei Qin
Journal:  Hum Cell       Date:  2022-10-15       Impact factor: 4.374

Review 7.  Extracellular vesicles as regulators of tumor fate: crosstalk among cancer stem cells, tumor cells and mesenchymal stem cells.

Authors:  Rafael Soares Lindoso; Federica Collino; Adalberto Vieyra
Journal:  Stem Cell Investig       Date:  2017-09-16

8.  Relative Expression of SOX2 and OCT4 in Oral Squamous Cell Carcinoma and Oral Epithelial Dysplasia.

Authors:  Narges Ghazi; Narges Aali; Vahid-Reza Shahrokhi; Farnaz Mohajertehran; Nasrollah Saghravanian
Journal:  Rep Biochem Mol Biol       Date:  2020-07

9.  Regulation of tumorigenesis in oral epithelial cells by defined reprogramming factors Oct4 and Sox2.

Authors:  Jinghua Cai; Baoxia He; Xinming Li; Minglei Sun; Alfred King-Yin Lam; Bin Qiao; Weiliu Qiu
Journal:  Oncol Rep       Date:  2016-06-03       Impact factor: 3.906

10.  Lovastatin Inhibits EMT and Metastasis of Triple-Negative Breast Cancer Stem Cells Through Dysregulation of Cytoskeleton-Associated Proteins.

Authors:  Chanjuan Zheng; Shichao Yan; Lu Lu; Hui Yao; Guangchun He; Sisi Chen; Ying Li; Xiaojun Peng; Zhongyi Cheng; Mi Wu; Qiuting Zhang; Guifei Li; Shujun Fu; Xiyun Deng
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.